The extent to which these outcomes might apply to the administration of recombinant human erythropoietin to patients with cancer, treated with chemotherapy to achieve du
Seetõttu on piisavalt tõendeid, et pidada inimese rekombinantse erütropoetiiniga ravimist patsientidele olulisel määral kahjulikuks.